Wading through policy is no easy task. But imagine policy as the white lines on the road, the boundaries within which FDA operates. Building our case, showing how Duchenne fits into those white lines and demonstrating how and when Accelerated Approval makes perfect sense is the purpose of PPMD’s white paper. …Continue
We are happy to report that additional members of Congress have signed on to the MD-CARE Act reauthorization. Find out who has signed on and how you can help thank them!
Updated 4/11/13: From 55 to now 69 total cosponsors! New additions in bold below We continue to make progress on the…See More
"This year I ran the Boston Marathon proudly representing RFOS. These are my experiences prior to the tragedy." - Chris Hancock
Boston, Patriots’ Day, Monday, April 15, 2013
"Accelerated Approval of any drug will be good for the Duchenne community – it will provide a clear position from FDA as to expectations and is likely to expedite other programs moving forward. If Sarepta or any other company receives Accelerated Approval, it unlocks a door, opens the pathway, suggests a level of understanding and expertise within FDA..." - Pat Furlong…See More